Ziltivekimab not checked

Novo Nordisk · COR-001 · MEDI5117

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
5 active
11 in total · 5 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Zilitivekimab will be administered subcutaneously once-monthly.”In the company’s words, NCT06200207 on ClinicalTrials.gov
Tested for
Acute Myocardial Infarction (AMI) (2 trials), Heart Failure, Systemic Inflammation, Cardiovascular Risk, Coronary Artery Disease, Coronary Atherosclerosis of Native Coronary Artery, Myocardial Infarction
Main trialPhase 3
“The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.”In the company’s words, NCT06200207 on ClinicalTrials.gov
Other names
COR-001 · MEDI5117

Other drugs for Acute Myocardial Infarction (AMI)

All 20 drugs for Acute Myocardial Infarction (AMI)

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 1 Oct 2026 A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
Phase 3Active, not recruiting 29 Jan 2027 ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Phase 3Recruiting 1 Sep 2028 Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
Phase 3Recruiting 14 Nov 2028 A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
Phase 3Terminated 3 Sep 2026 A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Phase 2Completed 26 Jun 2020 Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Phase 2Completed 3 Aug 2021 Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.
Phase 1/2Completed 11 Dec 2018 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001
Phase 1Terminated 28 Feb 2014 Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
Phase 1Completed 12 Jun 2024 A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation
Phase 2/3Authorised not given Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping (SPIDER)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ziltivekimab

Following is part of Solo: you see every change to Ziltivekimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in